Breakthrough in Cancer Gene Therapy: Researchers Achieve Promising Results with Lentivirus Vector

Strategic Insights -

A team of researchers at Cincinnati Children's Hospital Medical Center has made significant progress in cancer gene therapy, as revealed in a new study published in Molecular Therapy: Methods & Clinical Development. The research, focused on sickle cell anemia, demonstrates the efficacy of a modified gamma-globin lentivirus gene therapy in correcting the disease in mice and human xenograft models.

Key Takeaways:

  • The researchers created a G16D mutation in the gamma-globin gene to generate a lentiviral vector (LV) that increases fetal hemoglobin formation.
  • Preclinical batches of the LV showed high efficacy in correcting sickle cell anemia in mice, with sustained gene transfer and hematopoietic stem cell transduction.
  • CRISPR-mediated targeting of the proviruses into the LMO2 proto-oncogene reduced LMO2 activation compared to the SFFV g-RV vector.
  • The research concluded that the modified gamma-globin lentivirus gene therapy is suitable for translation into a clinical trial.
  • The study used two immunocompromised mouse models to assess gene transfer and engraftment of human HSCs, with results showing comparable engraftment and no detrimental effects on hematopoiesis up to 20 weeks post-transplant.

Statistics:

  • The study used preclinical batches of GbGM and GbGMI LV, showing high efficacy in correcting sickle cell anemia in mice.
  • The researchers observed sustained gene transfer in primary transplanted SCA mice, with high hematopoietic stem cell transduction in secondary transplanted mice.
  • The study demonstrated reduced LMO2 activation by both insulated and uninsulated LV compared to the SFFV g-RV vector, targeting the same locus.

Sources:

  • Preclinical efficacy of a modified gamma-globin lentivirus gene therapy in Berkeley sickle cell anemia mice and human xenograft models. Molecular Therapy: Methods & Clinical Development, 2025, 33(2):101439.
  • Molecular Therapy: Methods & Clinical Development - http://www.cell.com/molecular-therapy-family/methods/latest-content
  • Elsevier (publisher)